Horizon Discovery Group plc has announced the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.
Bayer today announced the selection of the new Executive Leadership Team for the Crop Science division, which will go into effect as of the closing of Bayer’s proposed acquisition of Monsanto. The closing is still subject to pending regulatory approval.
Sonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that Thai Lee, President and Chief Executive Officer of SHI International Corporation, has joined Sonde’s Board of Directors.
Neurimmune today announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. Dr. Buller joins Neurimmune’s executive team and brings 8 years of professional experience with biotech and pharma companies.
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.
Redx Pharma announced today that it has appointed Lisa Anson as Chief Executive Officer (CEO) and to its Board of Directors. Lisa will take up both roles on 1 June 2018. At that time Iain Ross, currently Executive Chairman, will revert to being Non-Executive Chairman.
Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.
Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.
Dr. Pearce Joins as ABIVAX Works with FDA and EMA on Next Stage Developments of its Clinical Product Candidates
Commense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.